Bilayer core-shell nanoparticle composite thermosensitive hydrogel co-loaded with bupivacaine and magnesium agent and application thereof
By using a bilayer core-shell nanoparticle composite thermosensitive gel co-loaded with bupivacaine and magnesium, rapid analgesia of bupivacaine and sustained anti-inflammatory release of magnesium ions are achieved, solving the multifunctional prevention problem of CIED bag complications, reducing infection rate and pain, and promoting anti-inflammatory response.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CHINESE ACADEMY OF MEDICAL SCIENCES FUWAI HOSPITAL SHENZHEN HOSPITAL (SHENZHEN SUN YAT-SEN CARDIOVASCULAR HOSPITAL)
- Filing Date
- 2026-04-29
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies lack postoperative pain management in preventing complications of implantable cardiovascular electronic devices (CIEDs) pockets, and cannot simultaneously meet the needs of acute analgesia and continuous postoperative anti-inflammatory/anti-infection. The potential of magnesium ions in anti-inflammatory and tissue repair functions has not been effectively utilized.
A bilayer core-shell nanoparticle composite thermosensitive gel co-loaded with bupivacaine and magnesium is used. The core is PLGA nanoparticles loaded with magnesium, and the outer shell is a lipid bilayer loaded with bupivacaine. Body temperature-induced gelation is used to form an in-situ drug reservoir, realizing rapid analgesic release of bupivacaine and sustained anti-inflammatory release of magnesium ions.
It significantly reduces the infection rate of pouches, alleviates early postoperative pain, promotes the polarization of M2 anti-inflammatory macrophages, and provides a multifunctional local drug delivery strategy that integrates analgesia, anti-inflammation, and anti-infection, thereby reducing the incidence of pouch complications.